GERON CORP Recognition of Deferred Revenue
GERON CORP (GERN) reported Recognition of Deferred Revenue of $35.00 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-05.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2015-11-05
- 2015-09-30: Recognition of Deferred Revenue 9 month $35.00M.
| Period end | Recognition of Deferred Revenue 9 month |
|---|---|
| 2015-09-30 | $35.00M 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |